NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING
Yoo Sun Kim(National Cancer Institute), Nitin Roper(Center for Cancer Research), Anagh Ray(National Cancer Institute), Afeez Adekunle Ishola(National Cancer Institute), Robin Sebastian(National Institutes of Health), Christophe E. Redon(Center for Cancer Research), Priyanka Gopal(Northwestern University), Barzin Y. Nabet(Gene Therapy Laboratory), Yves Pommier(National Cancer Institute), Mirit I. Aladjem(National Institutes of Health), Þorkell Andrésson(National Institutes of Health), David S. Shames(Gene Therapy Laboratory), Noémi Kedei(Center for Cancer Research), Anjali Dhall(National Cancer Institute), Nai-Yun Sun(National Cancer Institute), Velimir Gayevskiy(Rancho BioSciences (United States)), N Sato(National Cancer Institute), Alberto Chiappori(Moffitt Cancer Center), Mohamed E. Abazeed(Northwestern University), Liang Liu(Meizhou City People's Hospital), Sudipto Das(National Cancer Institute), Shraddha Rastogi(National Cancer Institute), Haobin Chen(Washington University in St. Louis), Moises J. Velez(Memorial Sloan Kettering Cancer Center), Min-Jung Lee(National Cancer Institute), Hongliang Zhang(National Natural Science Foundation of China), Briana Cortez(National Cancer Institute), Suresh Kumar(National Cancer Institute), Sivasish Sindiri(National Institutes of Health), Alan E. Bers(National Cancer Institute), Sarah Loew(National Cancer Institute)
Cited by 7
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
|Nature Medicine|2018|1.2k